InvestmentJul 13, 2026, 04:32 PM
CTT Pharma Registers 6.25M Shares for ELOC
AI Summary
CTT Pharmaceutical Holdings, Inc. has registered up to 6,250,000 shares of common stock for sale by RH2 Partners under an Equity Line of Credit (ELOC) agreement. While the company will not receive proceeds from the selling stockholder's sales, it may receive up to $10,000,000 from sales to the selling stockholder under the ELOC, which will be used for working capital and manufacturing equipment. The company, a development-stage entity with a history of losses and a 'going concern' qualification, acknowledges significant dilution risk, especially given its recent stock price of $0.08 per share.
Key Highlights
- CTT Pharma registered up to 6,250,000 shares for sale by RH2 Partners.
- Shares are related to an Equity Line of Credit (ELOC) agreement from September 19, 2025.
- Company may receive up to $10,000,000 from sales to the Selling Stockholder under the ELOC.
- Proceeds will be used for working capital, general corporate purposes, and $500,000 for manufacturing equipment.
- Common stock traded at $0.08 per share on June 26, 2026, on OTCQB.
- Company is a development-stage entity with a history of losses and a 'going concern' qualification.
- Management aims to limit ELOC use below $0.20/share to reduce dilution.
Price Impact
More from CTTH